---
layout: default
title: Adaptable Segmentation Pipeline for Diverse Brain Tumors with Radiomic-guided Subtyping and Lesion-Wise Model Ensemble
---

# Adaptable Segmentation Pipeline for Diverse Brain Tumors with Radiomic-guided Subtyping and Lesion-Wise Model Ensemble

**arXiv**: [2512.14648v1](https://arxiv.org/abs/2512.14648) | [PDF](https://arxiv.org/pdf/2512.14648.pdf)

**ä½œè€…**: Daniel CapellÃ¡n-MartÃ­n, Abhijeet Parida, Zhifan Jiang, Nishad Kulkarni, Krithika Iyer, Austin Tapp, Syed Muhammad Anwar, MarÃ­a J. Ledesma-Carbayo, Marius George Linguraru

**åˆ†ç±»**: cs.CV, eess.IV

**å‘å¸ƒæ—¥æœŸ**: 2025-12-16

**å¤‡æ³¨**: 12 pages, 5 figures, 3 tables. Algorithm presented at MICCAI BraTS 2025

---

## ðŸ’¡ ä¸€å¥è¯è¦ç‚¹

**æå‡ºå¯é€‚åº”è„‘è‚¿ç˜¤åˆ†å‰²æµç¨‹ï¼Œé€šè¿‡å½±åƒç»„å­¦å¼•å¯¼äºšåž‹è¯†åˆ«å’Œç—…ç¶çº§æ¨¡åž‹é›†æˆæå‡å¤šç±»åž‹è‚¿ç˜¤åˆ†å‰²æ€§èƒ½**

ðŸŽ¯ **åŒ¹é…é¢†åŸŸ**: **å¼ºåŒ–å­¦ä¹ **

**å…³é”®è¯**: `è„‘è‚¿ç˜¤åˆ†å‰²` `å¤šå‚æ•°MRI` `å½±åƒç»„å­¦` `æ¨¡åž‹é›†æˆ` `ç—…ç¶çº§å¤„ç†` `è‡ªé€‚åº”æµç¨‹` `ä¸´åºŠå½±åƒåˆ†æž` `BraTSæŒ‘æˆ˜`

## ðŸ“‹ æ ¸å¿ƒè¦ç‚¹

1. æ ¸å¿ƒé—®é¢˜ï¼šçŽ°æœ‰è„‘è‚¿ç˜¤åˆ†å‰²æ–¹æ³•éš¾ä»¥æ³›åŒ–åˆ°å¤šæ ·åŒ–çš„è‚¿ç˜¤ç±»åž‹ï¼ˆå¦‚å„¿ç«¥è‚¿ç˜¤ã€è„‘è†œç˜¤ã€è½¬ç§»ç˜¤ï¼‰ï¼Œä¸”ç¼ºä¹é’ˆå¯¹ç—…ç¶çº§ç‰¹æ€§çš„å®šåˆ¶å¤„ç†ã€‚
2. æ–¹æ³•è¦ç‚¹ï¼šæå‡ºæ¨¡å—åŒ–æµç¨‹ï¼Œç»“åˆå½±åƒç»„å­¦å¼•å¯¼çš„äºšåž‹è¯†åˆ«ã€ç—…ç¶çº§æ¨¡åž‹é›†æˆå’Œå®šåˆ¶åŽå¤„ç†ï¼Œå®žçŽ°è‡ªé€‚åº”åˆ†å‰²ã€‚
3. å®žéªŒæˆ–æ•ˆæžœï¼šåœ¨BraTS 2025å¤šä¸ªæŒ‘æˆ˜æµ‹è¯•é›†ä¸Šï¼Œæ€§èƒ½ä¸Žé¡¶çº§ç®—æ³•ç›¸å½“ï¼ŒéªŒè¯äº†æ–¹æ³•çš„ç¨³å¥æ€§å’Œæ³›åŒ–èƒ½åŠ›ã€‚

## ðŸ“ æ‘˜è¦ï¼ˆä¸­æ–‡ï¼‰

åœ¨å¤šå‚æ•°ç£å…±æŒ¯æˆåƒï¼ˆMRIï¼‰ä¸Šå®žçŽ°ç¨³å¥ä¸”å¯æ³›åŒ–çš„è„‘è‚¿ç˜¤åˆ†å‰²ä»ç„¶å›°éš¾ï¼Œå› ä¸ºè‚¿ç˜¤ç±»åž‹å·®å¼‚å¾ˆå¤§ã€‚BraTS 2025 Lighthouse Challenge åœ¨å¤šæ ·åŒ–çš„é«˜è´¨é‡æˆäººåŠå„¿ç«¥è‚¿ç˜¤æ•°æ®é›†ä¸Šå¯¹åˆ†å‰²æ–¹æ³•è¿›è¡ŒåŸºå‡†æµ‹è¯•ï¼šå›½é™…å¤šè”ç›Ÿå„¿ç«¥è„‘è‚¿ç˜¤åˆ†å‰²ï¼ˆPEDï¼‰ã€æœ¯å‰è„‘è†œç˜¤åˆ†å‰²ï¼ˆMENï¼‰ã€è„‘è†œç˜¤æ”¾ç–—åˆ†å‰²ï¼ˆMEN-RTï¼‰ä»¥åŠæ²»ç–—å‰åŽè„‘è½¬ç§»ç˜¤åˆ†å‰²ï¼ˆMETï¼‰ã€‚æˆ‘ä»¬æå‡ºäº†ä¸€ç§çµæ´»ã€æ¨¡å—åŒ–ä¸”å¯é€‚åº”çš„æµç¨‹ï¼Œé€šè¿‡é€‰æ‹©å’Œç»„åˆæœ€å…ˆè¿›çš„æ¨¡åž‹ï¼Œå¹¶åœ¨è®­ç»ƒå‰åŽåº”ç”¨è‚¿ç˜¤å’Œç—…ç¶ç‰¹å¼‚æ€§å¤„ç†æ¥æå‡åˆ†å‰²æ€§èƒ½ã€‚ä»ŽMRIä¸­æå–çš„å½±åƒç»„å­¦ç‰¹å¾æœ‰åŠ©äºŽæ£€æµ‹è‚¿ç˜¤äºšåž‹ï¼Œç¡®ä¿æ›´å¹³è¡¡çš„è®­ç»ƒã€‚å®šåˆ¶çš„ç—…ç¶çº§æ€§èƒ½æŒ‡æ ‡ç¡®å®šé›†æˆä¸­æ¯ä¸ªæ¨¡åž‹çš„å½±å“ï¼Œå¹¶ä¼˜åŒ–è¿›ä¸€æ­¥ç»†åŒ–é¢„æµ‹çš„åŽå¤„ç†ï¼Œä½¿å·¥ä½œæµç¨‹èƒ½å¤Ÿé’ˆå¯¹æ¯ä¸ªç—…ä¾‹å®šåˆ¶æ¯ä¸€æ­¥ã€‚åœ¨BraTSæµ‹è¯•é›†ä¸Šï¼Œæˆ‘ä»¬çš„æµç¨‹åœ¨å¤šä¸ªæŒ‘æˆ˜ä¸­å–å¾—äº†ä¸Žé¡¶çº§ç®—æ³•ç›¸å½“çš„æ€§èƒ½ã€‚è¿™äº›å‘çŽ°è¯å®žï¼Œå®šåˆ¶çš„ç—…ç¶æ„ŸçŸ¥å¤„ç†å’Œæ¨¡åž‹é€‰æ‹©èƒ½å¤Ÿäº§ç”Ÿç¨³å¥çš„åˆ†å‰²ï¼ŒåŒæ—¶ä¸å°†æ–¹æ³•é”å®šäºŽç‰¹å®šçš„ç½‘ç»œæž¶æž„ã€‚æˆ‘ä»¬çš„æ–¹æ³•åœ¨ä¸´åºŠå®žè·µä¸­å…·æœ‰å®šé‡è‚¿ç˜¤æµ‹é‡çš„æ½œåŠ›ï¼Œæ”¯æŒè¯Šæ–­å’Œé¢„åŽã€‚

## ðŸ”¬ æ–¹æ³•è¯¦è§£

**é—®é¢˜å®šä¹‰**ï¼šè®ºæ–‡æ—¨åœ¨è§£å†³å¤šå‚æ•°MRIä¸Šè„‘è‚¿ç˜¤åˆ†å‰²çš„ç¨³å¥æ€§å’Œæ³›åŒ–æ€§é—®é¢˜ï¼Œç‰¹åˆ«æ˜¯é’ˆå¯¹å¤šæ ·åŒ–çš„è‚¿ç˜¤ç±»åž‹ï¼ˆå¦‚å„¿ç«¥è‚¿ç˜¤ã€è„‘è†œç˜¤ã€è½¬ç§»ç˜¤ï¼‰ã€‚çŽ°æœ‰æ–¹æ³•çš„ç—›ç‚¹åœ¨äºŽï¼šè‚¿ç˜¤ç±»åž‹å·®å¼‚å¤§å¯¼è‡´å•ä¸€æ¨¡åž‹éš¾ä»¥é€‚åº”ï¼›ç¼ºä¹é’ˆå¯¹ç—…ç¶çº§ç‰¹æ€§çš„å®šåˆ¶å¤„ç†ï¼›è®­ç»ƒæ•°æ®ä¸å¹³è¡¡å½±å“æ¨¡åž‹æ€§èƒ½ã€‚

**æ ¸å¿ƒæ€è·¯**ï¼šè®ºæ–‡çš„æ ¸å¿ƒæ€è·¯æ˜¯è®¾è®¡ä¸€ä¸ªçµæ´»ã€æ¨¡å—åŒ–çš„åˆ†å‰²æµç¨‹ï¼Œé€šè¿‡é€‰æ‹©å’Œç»„åˆæœ€å…ˆè¿›çš„æ¨¡åž‹ï¼Œå¹¶åº”ç”¨è‚¿ç˜¤å’Œç—…ç¶ç‰¹å¼‚æ€§å¤„ç†æ¥æå‡æ€§èƒ½ã€‚è¿™åŒ…æ‹¬åˆ©ç”¨å½±åƒç»„å­¦ç‰¹å¾è¯†åˆ«è‚¿ç˜¤äºšåž‹ä»¥å¹³è¡¡è®­ç»ƒï¼Œä»¥åŠåŸºäºŽç—…ç¶çº§æŒ‡æ ‡ä¼˜åŒ–æ¨¡åž‹é›†æˆå’ŒåŽå¤„ç†ã€‚

**æŠ€æœ¯æ¡†æž¶**ï¼šæ•´ä½“æµç¨‹åŒ…å«å¤šä¸ªé˜¶æ®µï¼šé¦–å…ˆï¼Œä»ŽMRIæ•°æ®ä¸­æå–å½±åƒç»„å­¦ç‰¹å¾ï¼Œç”¨äºŽæ£€æµ‹è‚¿ç˜¤äºšåž‹å¹¶æŒ‡å¯¼æ•°æ®å¹³è¡¡ï¼›å…¶æ¬¡ï¼Œé€‰æ‹©å’Œè®­ç»ƒå¤šä¸ªåˆ†å‰²æ¨¡åž‹ï¼ˆå¯èƒ½åŸºäºŽä¸åŒç½‘ç»œæž¶æž„ï¼‰ï¼›ç„¶åŽï¼Œä½¿ç”¨å®šåˆ¶çš„ç—…ç¶çº§æ€§èƒ½æŒ‡æ ‡è¯„ä¼°æ¯ä¸ªæ¨¡åž‹ï¼Œå¹¶ç¡®å®šå…¶åœ¨é›†æˆä¸­çš„æƒé‡ï¼›æœ€åŽï¼Œåº”ç”¨ç—…ç¶æ„ŸçŸ¥çš„åŽå¤„ç†ï¼ˆå¦‚å½¢æ€å­¦æ“ä½œæˆ–é˜ˆå€¼è°ƒæ•´ï¼‰è¿›ä¸€æ­¥ç»†åŒ–é¢„æµ‹ç»“æžœã€‚æ•´ä¸ªæµç¨‹æ˜¯æ¨¡å—åŒ–çš„ï¼Œå…è®¸é’ˆå¯¹ä¸åŒè‚¿ç˜¤ç±»åž‹å’Œç—…ä¾‹è¿›è¡Œå®šåˆ¶ã€‚

**å…³é”®åˆ›æ–°**ï¼šæœ€é‡è¦çš„æŠ€æœ¯åˆ›æ–°ç‚¹åœ¨äºŽå°†å½±åƒç»„å­¦å¼•å¯¼çš„äºšåž‹è¯†åˆ«ä¸Žç—…ç¶çº§æ¨¡åž‹é›†æˆç›¸ç»“åˆï¼Œå®žçŽ°è‡ªé€‚åº”åˆ†å‰²ã€‚ä¸ŽçŽ°æœ‰æ–¹æ³•çš„æœ¬è´¨åŒºåˆ«åœ¨äºŽï¼šä¸ä¾èµ–äºŽå•ä¸€ç½‘ç»œæž¶æž„ï¼Œè€Œæ˜¯é€šè¿‡æ¨¡å—åŒ–è®¾è®¡çµæ´»ç»„åˆæ¨¡åž‹ï¼›å¼•å…¥ç—…ç¶çº§æŒ‡æ ‡è¿›è¡Œç²¾ç»†ä¼˜åŒ–ï¼Œè€Œéžä»…ä¾èµ–æ•´ä½“æ€§èƒ½ï¼›å¼ºè°ƒå¤„ç†æµç¨‹çš„å¯å®šåˆ¶æ€§ï¼Œä»¥é€‚åº”å¤šæ ·åŒ–çš„ä¸´åºŠåœºæ™¯ã€‚

**å…³é”®è®¾è®¡**ï¼šå…³é”®è®¾è®¡åŒ…æ‹¬ï¼šå½±åƒç»„å­¦ç‰¹å¾æå–ç”¨äºŽäºšåž‹åˆ†ç±»ï¼ˆå…·ä½“ç‰¹å¾é›†æœªçŸ¥ï¼Œä½†å¯èƒ½åŸºäºŽçº¹ç†ã€å½¢çŠ¶ç­‰ï¼‰ï¼›æ¨¡åž‹é›†æˆç­–ç•¥åŸºäºŽç—…ç¶çº§æŒ‡æ ‡ï¼ˆå¦‚Diceç³»æ•°æˆ–æ•æ„Ÿåº¦ï¼‰åŠ¨æ€åŠ æƒï¼›åŽå¤„ç†æ­¥éª¤å¯èƒ½æ¶‰åŠç—…ç¶çº§çš„å½¢æ€å­¦æ“ä½œæˆ–é˜ˆå€¼è°ƒæ•´ï¼Œä»¥æ¶ˆé™¤å™ªå£°å¹¶æå‡è¾¹ç•Œç²¾åº¦ã€‚æŸå¤±å‡½æ•°å’Œç½‘ç»œç»“æž„ç»†èŠ‚æœªåœ¨æ‘˜è¦ä¸­æ˜Žç¡®ï¼Œä½†æµç¨‹å…è®¸é›†æˆå¤šç§æœ€å…ˆè¿›æ¨¡åž‹ï¼ˆå¦‚U-Netå˜ä½“æˆ–Transformeræž¶æž„ï¼‰ã€‚

## ðŸ“Š å®žéªŒäº®ç‚¹

åœ¨BraTS 2025 Lighthouse Challengeçš„æµ‹è¯•é›†ä¸Šï¼Œè¯¥æµç¨‹åœ¨å¤šä¸ªå­æŒ‘æˆ˜ï¼ˆåŒ…æ‹¬PEDã€MENã€MEN-RTã€METï¼‰ä¸­å–å¾—äº†ä¸Žé¡¶çº§ç®—æ³•ç›¸å½“çš„æ€§èƒ½ã€‚å…·ä½“æ€§èƒ½æ•°æ®æœªåœ¨æ‘˜è¦ä¸­æä¾›ï¼Œä½†ç»“æžœè¡¨æ˜Žæ–¹æ³•åœ¨å¤šæ ·åŒ–çš„è‚¿ç˜¤ç±»åž‹ä¸Šè¡¨çŽ°ç¨³å¥ï¼ŒéªŒè¯äº†ç—…ç¶çº§å¤„ç†å’Œæ¨¡åž‹é›†æˆçš„æœ‰æ•ˆæ€§ã€‚æå‡å¹…åº¦ä½“çŽ°åœ¨æ³›åŒ–èƒ½åŠ›çš„å¢žå¼ºï¼Œæ— éœ€é”å®šç‰¹å®šç½‘ç»œæž¶æž„å³å¯è¾¾åˆ°é«˜åˆ†å‰²ç²¾åº¦ã€‚

## ðŸŽ¯ åº”ç”¨åœºæ™¯

è¯¥ç ”ç©¶åœ¨ä¸´åºŠåŒ»å­¦å½±åƒåˆ†æžé¢†åŸŸå…·æœ‰é‡è¦åº”ç”¨ä»·å€¼ï¼Œç‰¹åˆ«æ˜¯è„‘è‚¿ç˜¤çš„å®šé‡æµ‹é‡ã€‚æ½œåœ¨åº”ç”¨åŒ…æ‹¬ï¼šè¾…åŠ©åŒ»ç”Ÿè¿›è¡Œè„‘è‚¿ç˜¤ï¼ˆå¦‚å„¿ç«¥è‚¿ç˜¤ã€è„‘è†œç˜¤ã€è½¬ç§»ç˜¤ï¼‰çš„è¯Šæ–­å’Œé¢„åŽè¯„ä¼°ï¼›æ”¯æŒæ”¾ç–—è§„åˆ’ä¸­çš„é¶åŒºå‹¾ç”»ï¼›ä¿ƒè¿›å¤šä¸­å¿ƒç ”ç©¶ä¸­çš„æ ‡å‡†åŒ–åˆ†å‰²ã€‚æœªæ¥å½±å“å¯èƒ½æŽ¨åŠ¨ä¸ªæ€§åŒ–åŒ»ç–—å’Œè‡ªåŠ¨åŒ–å½±åƒåˆ†æžå·¥å…·çš„å‘å±•ï¼Œæé«˜ä¸´åºŠå·¥ä½œæ•ˆçŽ‡å’Œå‡†ç¡®æ€§ã€‚

## ðŸ“„ æ‘˜è¦ï¼ˆåŽŸæ–‡ï¼‰

> Robust and generalizable segmentation of brain tumors on multi-parametric magnetic resonance imaging (MRI) remains difficult because tumor types differ widely. The BraTS 2025 Lighthouse Challenge benchmarks segmentation methods on diverse high-quality datasets of adult and pediatric tumors: multi-consortium international pediatric brain tumor segmentation (PED), preoperative meningioma tumor segmentation (MEN), meningioma radiotherapy segmentation (MEN-RT), and segmentation of pre- and post-treatment brain metastases (MET). We present a flexible, modular, and adaptable pipeline that improves segmentation performance by selecting and combining state-of-the-art models and applying tumor- and lesion-specific processing before and after training. Radiomic features extracted from MRI help detect tumor subtype, ensuring a more balanced training. Custom lesion-level performance metrics determine the influence of each model in the ensemble and optimize post-processing that further refines the predictions, enabling the workflow to tailor every step to each case. On the BraTS testing sets, our pipeline achieved performance comparable to top-ranked algorithms across multiple challenges. These findings confirm that custom lesion-aware processing and model selection yield robust segmentations yet without locking the method to a specific network architecture. Our method has the potential for quantitative tumor measurement in clinical practice, supporting diagnosis and prognosis.

